- Home
- BMGL vs IGMS Comparison
BMGL vs IGMS Comparison
Compare BMGL & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMGL
- IGMS
- Stock Information
- Founded
- BMGL 2001
- IGMS 1993
- Country
- BMGL Singapore
- IGMS United States
- Employees
- BMGL N/A
- IGMS N/A
- Industry
- BMGL
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- BMGL
- IGMS Health Care
- Exchange
- BMGL NYSE
- IGMS Nasdaq
- Market Cap
- BMGL 78.3M
- IGMS 82.1M
- IPO Year
- BMGL 2025
- IGMS 2019
- Fundamental
- Price
- BMGL $4.77
- IGMS $1.13
- Analyst Decision
- BMGL
- IGMS Hold
- Analyst Count
- BMGL 0
- IGMS 8
- Target Price
- BMGL N/A
- IGMS $6.14
- AVG Volume (30 Days)
- BMGL 78.2K
- IGMS 152.8K
- Earning Date
- BMGL 01-01-0001
- IGMS 05-20-2025
- Dividend Yield
- BMGL N/A
- IGMS N/A
- EPS Growth
- BMGL 16.23
- IGMS N/A
- EPS
- BMGL 0.09
- IGMS N/A
- Revenue
- BMGL $7,428,776.00
- IGMS $2,679,000.00
- Revenue This Year
- BMGL N/A
- IGMS $121.76
- Revenue Next Year
- BMGL N/A
- IGMS $46.83
- P/E Ratio
- BMGL $50.27
- IGMS N/A
- Revenue Growth
- BMGL 3.32
- IGMS 25.77
- 52 Week Low
- BMGL $3.63
- IGMS $0.92
- 52 Week High
- BMGL $5.50
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- BMGL N/A
- IGMS 39.53
- Support Level
- BMGL N/A
- IGMS $1.11
- Resistance Level
- BMGL N/A
- IGMS $1.22
- Average True Range (ATR)
- BMGL 0.00
- IGMS 0.11
- MACD
- BMGL 0.00
- IGMS -0.02
- Stochastic Oscillator
- BMGL 0.00
- IGMS 5.56
About BMGL BASEL MEDICAL GROUP LTD
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. Key revenue is generated from Singapore.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.